The role of anorexia nervosa in secondary osteoporosis development with the risk for low energy fractures by Horst-Sikorska, Wanda & Ignaszak-Szczepaniak, Magdalena
45
PRACE POGLĄDOWE/REVIEWS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 1/2011
ISSN 0423–104X
Prof. Wanda Horst-Sikorska MD, Department of Family Medicine, Poznan University of Medical Sciences, Przybyszewskiego St. 39,
60–355 Poznań, Poland, tel.: +48 61 869 11 44, fax: +48 61 869 11 43, e-mail: zmrw2l@amp.edu.pl
The role of anorexia nervosa in secondary osteoporosis
development with the risk for low energy fractures
Rola anorexia nervosa w rozwoju wtórnej osteoporozy z uwzględnieniem
ryzyka złamań kości
Wanda Horst-Sikorska, Magdalena Ignaszak-Szczepaniak
Chair and Department of Family Medicine, Poznan University of Medical Sciences, Poland
Abstract
Anorexia nervosa (AN) has in recent years become considerably more common. The disease primarily affects girls and young women, and
also boys and young men. AN is a risk factor for secondary osteoporosis. AN-related metabolic disturbances lead to diminished bone
quality and increased risk of fractures. The consequences of low energy fractures are the main causes of death in women with AN. Hormo-
nal disturbances (e.g. hypoestrogenism, increased levels of ghrelin and Y peptide, changes in leptin and endocannabinoid levels), as well
as the mechanisms involved in bone resorption (RANK/RANKL/OPG), are considered to be of great importance for anorectic bone quality.
The risk of osteoporotic, non-vertebral fractures in AN patients is significantly higher than in healthy women. An improvement of bone
mineral density is possible after substantial body mass increase. Weight loss, in conjunction with a well-balanced, controlled diet, is the key
to correct peak bone mass levels, and diminishes the risk of osteoporosis with its consequence of low energy bone fractures.
(Pol J Endocrinol 2011; 62 (1): 45–47)
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Streszczenie
W ostatnich latach obserwuje się znaczny wzrost częstości występowania jadłowstrętu psychicznego (AN, anorexia nervosa). Problem
dotyczy zwłaszcza dziewcząt i młodych kobiet, ale coraz częściej dotyka także chłopców i młodych mężczyzn. Anorexia nervosa jest czyn-
nikiem ryzyka rozwoju osteoporozy wtórnej. Zaburzenia metaboliczne, występujące u pacjentów z AN doprowadzają do pogorszenia jakoś-
ci kości i w konsekwencji do zwiększenia ryzyka złamań. Ich następstwa są główną przyczyną śmiertelności chorych z AN. U podstaw
zmian jakości kości wymienia się zaburzenia hormonalne (m.in. hypoestrogenizm, wzrost greliny i peptydu Y, nieprawidłowe stężenia
leptyny i endokanabinoidów) oraz wynikające z tego faktu zakłócenia mechanizmu regulacji resorpcji kostnej (układ RANK/RANKL/
/OPG). Ryzyko pozakręgowych osteoporotycznych złamań kości u kobiet z AN jest znacząco wyższe niż u zdrowych rówieśniczek.
Poprawa gęstości mineralnej kości następuje dopiero po uzyskaniu znaczącego wzrostu masy ciała. Przeciwdziałanie utracie wagi, nadzór
nad prawidłowym odżywianiem sa kluczem do osiągnięcia prawidłowej szczytowej masy kostnej, zmniejszenia ryzyka osteoporozy
i złamań niskoenergetycznych kości. (Endokrynol Pol 2011; 62 (1): 45–47)
Słowa kluczowe: jadłowstręt psychiczny, ryzyko złamań, wtórna osteoporoza
Nutritional disorders such as anorexia nervosa (AN) and
bulimia are considered to be psychosomatic disturbanc-
es, the incidence of which has grown over recent years.
Girls and young women predominate in the general,
AN-affected population. However, the disease is in-
creasingly being diagnosed in boys and young men. AN
is manifested by obsessive self-control of body shape,
associated with grossly distorted perception of the suf-
ferer’s own body and a morbid fear of fatness. Affected
patients refuse meals, while hiding the fact that food
and eating restrictions are often combined with self-in-
duced vomiting. Their attention is focused on meals,
weight control and a general concentration on eating
and foods. Patients’  weight plunges dramatically, while
they impose more and more extreme dietary limitations
on themselves.
Subjective symptoms of anorectic patients are scarce.
Patients are convinced that a slim body shape is the key
to a successful life, thus positively perceiving any weight
control possibilities. They are unable to perceive their
true emaciation, while evaluating their body shape with
shame as all the time being too fat. Secondary amenor-
rhoea is a characteristic feature in such women. Patients
also complain of dizziness and headaches, while mete-
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orism and constipation are other frequent symptoms.
Patients are often of above average intelligence, with
high scores at school/university being obvious manifes-
tations of a demand for success.
Medical examination of patients with anorexia finds
a total  disappearance of adipose tissue bordering on
cachexia, together with bradycardia and low arterial
blood pressure. The skin is cool and pale grey, often
with very fine hair, and head hair is thinning. Hands
are cold and sweaty. In advanced forms of the disease,
lipoprotein oedemas of hands and feet are observed.
The preserved tissue of mammary glands is a common
feature,  in contrast to the loss of adipose tissue in other
body regions. Features of dehydration are simulta-
neously observed. Metabolic disorders, which occur in
anorectic patients, lead to bone quality deterioration
and, in consequence, to low energy bone fractures.
 Studies have found that 40% of anorectic females
experience periods of overeating and bulimia. In cases
when a non-anorectic subject demonstrates such behav-
iour more often than twice a week, over a period long-
er than three months, bulimia would be diagnosed.
Bulimia is characterised by paroxysmal overeating, fol-
lowed by compensatory behaviour such as self-induced
vomiting, fasting, the use of diuretics and laxatives,
enemas and excessive physical exercise.
Anorexia nervosa is a dangerous disease which, de-
spite treatment, carries a high risk of death. According
to the literature, the consequences of osteoporotic bone
fractures are at the base of disease complications and
death among patients with anorexia. Therefore, os-
teoporosis should be acknowledged as one of the more
serious, anorexia-related threats [1].
The aetiopathogenesis of the disease has yet to be
fully understood. Some role in appetite distortion can
be played by the disturbed synthesis of leptin and en-
docannabinoid, as well as of ghrelin, IGF-1 and melato-
nin [2–4]. Identified disorders of hormone and cytok-
ine secretion can, however, be of secondary importance
and they should thus be treated as a consequence of
the disease, rather than its direct cause. This thesis is
supported by the fact that, even if hormonal supple-
mentation can induce menstruation, it does not mean
a simultaneous withdrawal of the metabolic conse-
quences of anorexia, for example those concerning min-
eral bone density, which improves only after a gain in
body weight and better nutrition.
A diagnosis of anorexia is obtained from BMI values
and when a patient demonstrates compulsive concen-
tration on her/his body weight. Amenorrhoea is a char-
acteristic feature of the disease in women.
In 20–50% of patients with anorexia, secondary os-
teoporosis is diagnosed, associated with elevated bone
fracture risks, especially in extravertebral locations [5].
Hormonal disorders, mainly hypoestrogenism, hypoan-
drogenism and hypercortisolemia, are at the base of
anorexia accompanying bone quality changes [1, 6].
Moreover, anorectic patients present with decreased
insulin-like growth factor 1 (IGF-1) concentrations and
elevated levels of the growth hormone, gherlin and
peptide YY. In consequence of the above-mentioned
hormonal disorders, young girls do not achieve age-
optimal bone mass. It is assumed that it is the disturbed
control of bone resorption activity which plays a signifi-
cant role in the aetiopathogenesis of osteoporosis in an-
orectic patients. Some reduction of 17 beta oestradiol lev-
els in the blood serum of patients reduces the synthesis
of osteoprotegerin (OPG), a protein which suppresses the
RANK/RANKL link (NK-kB, nuclear kappa-beta factor).
This link plays an important role in the activation of osteo-
clasts. The connection of the TANK receptor with the
kappa-beta factor induces a differentiation process of
cells in the lines of macrophages and monocytes into
preosteoclasts. The disturbed, mutual RANK/RANKL/
/OPG system shifts the trend of bone changes towards
an excessive activation of osteoclasts, resulting in ex-
cessive bone resorption and bone mineral mass reduc-
tion [7].
 The role of leptin in the aetiopathogenesis of anor-
exia is still not entirely explained. Leptin concentration
is thought to play a certain role in cyclic oestrogen se-
cretion control. Disorders of its secretion can be an ad-
ditional factor affecting hypothalamic control of the
menstrual cycle. Some anorectic patients present with
secretion disorders of melatonin, especially in its noc-
turnal phase, which may additionally impair the mutu-
al balance mechanism of the RANK/RANKL/OPG sys-
tem [6, 7].
The lack of vitamins and mineral compounds, nor-
mally supplied via food, is also very important in the
mechanism of bone mass loss, as observed in the course
of anorexia. The deficits of food, vitamins (including
vitamin D3), calcium and other mineral compounds,
additionally disturb bone metabolism. Calcium assimi-
lation from foods is more effective than from pharma-
cological agents. Also dietary calcium is better incorpo-
rated into bones. No intake of dietary supplements can
be certain to provide comparable effects [8].
Abnormal concentrations of the biochemical mark-
ers of bone metabolism confirm the occurrence of bone
metabolism disturbances in anorectic patients: an in-
creased level of resorption markers (CTX-C, the termi-
nal, cross-linked telopeptide of type I collagen alpha
chain), with no simultaneous increase of bone-forma-
tion marker levels (P1NP, N-terminal propeptide of type 1
procollagen) [9]. Interesting observations concern the
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differences, identified in the course of bone metabolism
disorders, between young girls and more mature wom-
en. In the former, the total rate of bone metabolism cy-
cles decreases, unlike in young women who demon-
strate a growth of bone resorption intensity with a si-
multaneous lack of the compensatory acceleration of
bone-formation process dynamics [10].
In girls with anorexia who are diagnosed before the
age of 14, total bone mineral density may still remain
within the range of values regarded as normal. How-
ever, BMD values, measured in vertebral bodies and in
the proximal femoral bone, are already lower in that
period of life as opposed to those in their healthy peers
[11]. Also in boys, BMD reductions have been observed
in various regions of the skeleton, with a distinctive
slowdown of bone metabolism rate (confirmed by stud-
ied concentrations of the biochemical markers of bone
metabolism), observed at the age in which the largest
bone mass increase is but a physiological standard [10].
The younger the patient with anorexia, the lower
the so-called peak bone mass they achieve. Optimal
bone mass levels, obtained in young age, are of key sig-
nificance for alleviating a later, age-related, gradual
BMD decrease, especially that experienced after the
menopause.
Metabolic disorders, which accompany anorexia,
result in bone quality deterioration and BMD reduction,
in particular, within the cortical bone, including im-
paired bone strength. Studies have demonstrated a dis-
tinctly higher risk of low energy bone fractures [12].
A meta-analysis, performed by Rigotti in anorectic wom-
en, confirmed the relationship between BMD reduction
and increased fracture risk. In fact, the incidence of ex-
travertebral, osteoporotic bone fractures in women with
anorexia is statistically significantly higher than that in
their normally-eating peers. In other nutritional disor-
ders, such as bulimia nervosa, neither the BMD drop
nor the fracture risk rise is so distinctive or attains the
level of statistical significance [5].
An abnormal course of bone transformations, which
accompany anorexia nervosa in contrast to bone me-
tabolism disorders, which accompany amenorrhoea,
does not respond to standard therapeutic management.
In cases of menstrual disorders of hypothalamic origin,
the standard oestrogen-progesterone therapy improves
bone mass, but it fails to induce the same effect in girls
with anorexia. BMD improvement can be expected only
after a considerable increase of BMI [11, 13].
Similarly, studies performed for therapy efficiency
evaluation in cases of secondary osteoporosis in anorec-
tic patients do not provide results which can be com-
pared to therapy effects of other forms of osteoporosis.
Clinical trials, including alendronate administration in
AN patients, have provided very ambiguous results,
ranging from reports which confirm the favourable ef-
fects of the therapy to others which claim no improve-
ment at all [14].
Anorexia nervosa is now identified also in boys and
young men. Keeping in mind the obvious differences,
such as the lack of secondary amenorrhoea, the other
symptoms are fairly similar. Changes in the bone sys-
tem include BMD reduction in many regions of the skel-
eton. A slower rate of bone metabolism and reduced
levels of achieved peak bone mass are the observed fea-
tures [3].
Studies into the efficacy of applied therapy modes
indicate, as with women, that the earliest possible diag-
nosis and high levels of persuasion to induce proper
nutrition and effective body weight loss prevention are
of key importance for the therapeutic prognosis [15].
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